https://www.science.org/doi/10.1126/science.adl0867
"More than 4 years into the global COVID-19 pandemic, widespread infection with
severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) has left millions
of people around the world with Long Covid, which describes the constellation
of post-acute and long-term adverse health effects caused by the infection.
Evidence generated by the scientific community—with formidable contributions
from patient-led research teams—has provided a thorough understanding of the
epidemiology and clinical manifestations of Long Covid. Understanding the
biologic underpinnings of this disease is also improving, along with evidence
that vaccination and antivirals can help prevent it. Yet despite this progress,
prevention efforts have stalled, there is uncertainty about governments’
long-term commitment to address research needs in this area, and there has yet
to be a treatment option validated with randomized controlled trials (RCTs).
Long Covid can manifest in people across the life span (from children to older
adults) and across race and ethnicity, sex, and baseline health status. It is a
complex nonmonolithic multisystemic disease with sequelae across almost all
organ systems. Long Covid is likely a disease with many subtypes that may have
different risk factors (genetic, environmental, etc.) and distinct biologic
mechanisms that may respond differently to treatments. For example, the
prototypical (classic) form of Long Covid (with brain fog, fatigue,
dysautonomia, and postexertional malaise) is more common in younger adults and
in females. Other forms of Long Covid, including those with cardiovascular and
metabolic sequelae, are manifest more often in older adults and those with
comorbidities. A common risk across all types of Long Covid is severity of
acute infection; the risk—on the relative scale—increases according to the
severity of the acute infection. However, despite the lower relative risk, more
than 90% of cases occur in people who had mild SARS-CoV-2 infection, owing to
the much higher prevalence of mild cases."
Via Violet Blue’s
Pandemic Roundup: February 29, 2024
https://www.patreon.com/posts/pandemic-roundup-99442377
Cheers,
*** Xanni ***
--
mailto:xanni@xanadu.net Andrew Pam
http://xanadu.com.au/ Chief Scientist, Xanadu
https://glasswings.com.au/ Partner, Glass Wings
https://sericyb.com.au/ Manager, Serious Cybernetics
